L

Lucid Diagnostics Inc
NASDAQ:LUCD

Watchlist Manager
Lucid Diagnostics Inc
NASDAQ:LUCD
Watchlist
Price: 1.14 USD Market Closed
Market Cap: 156.4m USD

Lucid Diagnostics Inc
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Lucid Diagnostics Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
L
Lucid Diagnostics Inc
NASDAQ:LUCD
EPS (Diluted)
-$1
CAGR 3-Years
-9%
CAGR 5-Years
-54%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
EPS (Diluted)
$5
CAGR 3-Years
0%
CAGR 5-Years
17%
CAGR 10-Years
6%
Boston Scientific Corp
NYSE:BSX
EPS (Diluted)
$1
CAGR 3-Years
64%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
Stryker Corp
NYSE:SYK
EPS (Diluted)
$7
CAGR 3-Years
6%
CAGR 5-Years
10%
CAGR 10-Years
9%
Abbott Laboratories
NYSE:ABT
EPS (Diluted)
$8
CAGR 3-Years
21%
CAGR 5-Years
34%
CAGR 10-Years
10%
Intuitive Surgical Inc
NASDAQ:ISRG
EPS (Diluted)
$7
CAGR 3-Years
26%
CAGR 5-Years
21%
CAGR 10-Years
17%
No Stocks Found

Lucid Diagnostics Inc
Glance View

Market Cap
149.3m USD
Industry
Health Care

Lucid Diagnostics, Inc. develops medical testing devices. The company is headquartered in New York City, New York. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). Its products include EsoCheck and EsoGuard. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in an office procedure. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. EsoGuard is a bisulfite-converted next generation sequencing (NGS) deoxyribonucleic acid (DNA) assay performed on surface esophageal cells collected with EsoCheck. The firm is a subsidiary of PAVmed Inc.

LUCD Intrinsic Value
HIDDEN
Show

See Also

What is Lucid Diagnostics Inc's EPS (Diluted)?
EPS (Diluted)
-1.1 USD

Based on the financial report for Dec 31, 2024, Lucid Diagnostics Inc's EPS (Diluted) amounts to -1.1 USD.

What is Lucid Diagnostics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-54%

Over the last year, the EPS (Diluted) growth was 17%. The average annual EPS (Diluted) growth rates for Lucid Diagnostics Inc have been -9% over the past three years , -54% over the past five years .

Back to Top